GlassScriptPhysician profile
Jeffrey Novak
NPI 1700969714
$7,392.04
in general payments reported to CMS, 2019-2025
29 companies · $1,204 in 2025
The $1,204 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,100 · 2020: $422 · 2021: $720 · 2022: $1,013 · 2023: $1,801 · 2024: $1,131 · 2025: $1,204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,136.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,467.21 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $750.23 | 2019-2025 | Xifaxan |
| Janssen Biotech, INC. | $536.54 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $527.67 | 2019-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $320.13 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $253.22 | 2021-2023 | Zeposia |
| Merck Sharp & Dohme LLC | $226.27 | 2019-2023 | Dificid |
| Ardelyx, INC. | $216.87 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $211.27 | 2025 | Rezdiffra |
| Qol Medical, LLC | $205.01 | 2019-2025 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $179.31 | 2022-2025 | Dupixent |
| Pfizer INC. | $166.61 | 2019-2025 | |
| Braintree Laboratories, INC. | $156.29 | 2020-2025 | Suflave, Sutab |
| Celgene Corporation | $150.02 | 2021-2023 | Zeposia |
| Evoke Pharma, INC. | $148.62 | 2021-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $141.19 | 2019-2023 | Rebyota |
| Vivus LLC | $115.93 | 2023-2025 | Qsymia |
| Ironwood Pharmaceuticals, INC | $109.81 | 2020-2024 | Linzess |
| Intercept Pharmaceuticals, INC. | $92.84 | 2019-2023 | Ocaliva |
| Redhill Biopharma INC. | $86.68 | 2021-2023 | Talicia |
| Allergan, INC. | $70.73 | 2019 | |
| Ucb, INC. | $58.06 | 2019 | |
| Phathom Pharmaceuticals, INC. | $48.25 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $42.00 | 2021-2023 | |
| Lilly USA, LLC | $34.36 | 2024-2025 | Omvoh |
| Daiichi Sankyo INC. | $34.28 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $15.26 | 2022 | |
| Shield Therapeutics INC | $15.05 | 2023 | Accrufer |
| Gilead Sciences, INC. | $12.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Novak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.